About Us

Modulus Oncology. A first in class oncology portfolio company modulating the AM2 receptor for improved patient outcomes in tumour types poorly served by existing therapies.

History

Having successfully secured £5m of grant funding from the Wellcome Trust, Professor Tim Skerry and a team of TUOS researchers supported by pharma industry collaborators set out to target the AM2R with small molecule antagonists with the goal of creating a new class of anti-cancer therapeutics. Using a sophisticated structure/activity relationship (SAR) model, the team successfully generated a series of novel first in class AM2R antagonists and went on to validate and designate a development candidate. 

The Company’s lead clinical candidate (SHF-1036), shows favourable target engagement coupled with an encouraging pharmacokinetic and toxicity profile. It has already generated strong biological proof-of-concept data, demonstrating anti-tumour activity in pancreatic cancer models. The team’s deep understanding of the intricacies of AM2R biology and the necessary features required for optimal target engagement are key differentiators for Modulus. The inclusion of pharmaceutical collaborators in the discovery programme coupled with the support of successful biotech entrepreneurs as founders of the company have established a strong foundation for the future development of Modulus Oncology.  The research programme which underpins Modulus Oncology was recently published here.


Executive Team

Professor Tim Skerry

Professor Tim Skerry

Co-Founder and Chief Scientific Officer (CSO)

Find out more
Dr Gareth Richards

Dr Gareth Richards

Co-Founder and VP of Preclinical/Biology

Find out more
Dr Alan Wise

Dr Alan Wise

Chief Executive Officer (CEO)

Find out more
Professor Glen Clack

Professor Glen Clack

Chief Medical Officer (CMO)

Find out more
Dr Clare Wareing

Dr Clare Wareing

Chief Business Officer (CBO)

Find out more
Keith Murdoch

Keith Murdoch

Chief Financial Officer (CFO)

Find out more
Dr Manuelle Debunne

Dr Manuelle Debunne

Director of Preclinical programme

Find out more
Professor Andrew V. Biankin

Professor Andrew V. Biankin

Scientific Advisor

Find out more
Professor Joseph Harrity

Professor Joseph Harrity

Co-Founder and Scientific Advisor

Find out more

Board of Directors

Dr Alan Wise

Dr Alan Wise

Chief Executive Officer (CEO)

Find out more
Professor Tim Skerry

Professor Tim Skerry

Co-Founder and Chief Scientific Officer (CSO)

Find out more
Andy Hogben

Andy Hogben

Non-executive Director

Find out more